论文部分内容阅读
膀胱癌在泌尿系肿瘤中发病率很高,病理诊断为非肌层浸润性膀胱癌(NMIBC)患者治疗方案基本相同,以经尿道膀胱肿瘤电切(TURBT)及术后膀胱灌注化疗为主,术后复发进展较为常见。现普遍认为肿瘤是一种免疫性疾病,对癌细胞靶向杀伤且通过调节免疫系统功能有可能降低复发进展率。本文对重组卡介苗、基因疗法、肿瘤细胞疫苗、树突状细胞疫苗、单克隆抗体等免疫治疗手段进行归纳总结,分析其在膀胱癌中的应用前景,以期为基础实验研究提供新思路,为其在临床应用奠定理论基础。
The incidence of bladder cancer in urological tumors is very high. The pathological diagnosis of patients with non-muscle invasive bladder cancer (NMIBC) is basically the same. TURBT and postoperative bladder infusion chemotherapy are the main methods. Postoperative recurrence is more common. It is generally accepted that the tumor is an immune disease, targeted killing of cancer cells and may reduce the rate of progress of the recurrence by regulating the function of the immune system. This article summarizes the immunotherapy methods such as recombinant BCG, gene therapy, tumor cell vaccine, dendritic cell vaccine, monoclonal antibody and so on, and analyzes its application foreground in bladder cancer with a view to providing new ideas for the basic experimental research. Lay the theoretical foundation in clinical application.